|
Description  |
|
|
BACKGROUND OF THE INVENTION
The present invention relates to contact irradiation treatment of malignant
tumors by laser energy, and more particularly to interstitial applications
deeply inside the body of a subject.
Non-contact treatment of surface tumors by laser irradiation has become an
accepted medical technique for coagulation, necrosis, and palliation of
esophageal, bronchial, colorectal and bladder tumors.
Medical researchers are now seriously considering laser techniques for
treating deep seated tumors in the liver, pancreas, prostate, and even in
the brain. Interstitial techniques of local hyperthermia deep inside the
body offers a safe and sometimes the only effective way of treating such
tumors. These techniques can be minimally invasive surgically, requiring
only a tiny stab incision, dramatically improving patient comfort and
chances of survival and reducing convalescence and recovery time in
treatment involving the liver for instance.
An apparatus and method for locally generating hyperthermia-induced
coagulation necrosis in tissue masses located deeply within the body are
described in applicant's co-pending U.S. patent application Ser. No.
07/534,931, filed Jun. 8, 1990 for "APPARATUS AND METHOD FOR INTERSTITIAL
LASER THERAPY". As described in that application, low power laser
radiation is introduced into the target tissue mass using an optical fiber
extending through a cannula which has been inserted directly into the
tissue mass. By activating the laser only during withdrawal movement of
the cannula and maintaining a small fluid bolus at the fiber tip,
effective and reproducible coagulation of tumor tissue is attained without
charring or melting of the probe.
One problem in carrying out interstitial hyperthermia is controlling the
temperature of the tissue while it is being irradiated. Hyperthermia
destroys both tumor tissue and normal tissue. Laser energy delivered by
optical fibers inserted directly into tissue provides an excellent form of
local hyperthermia for deep seated tumors of clinical importance (in the
liver and pancreas, for example). For this to be of maximum effect,
treatment parameters required to destroy all the tumor must be known,
namely size of the tumor, laser power and exposure time, and number and
location of treatment points. There should be minimal damage to adjacent
normal tissue, and subsequent healing of all treated areas, so that
acceptable function and mechanical structure of the organ is maintained.
While heating alone, at a sufficient elevated temperature and for a
sufficient time, is known to destroy tumor tissue, there is considerable
experimental and clinical evidence of additional advantages from
interaction between Nd:YAG laser radiation and cancer cells. This is
believed to be caused by the direct absorption of laser light by the
cancer cells. This is reported in Lasers in Surgery and Medicine Volume 8,
Pages 254-258 (1988) in an article entitled "LASERTHERMIA: A New
Computer-Controlled Contact Nd:YAG System for Interstitial Local
Hyperthermia".
Thus, there appears to be some cumulative advantage in providing the heat
energy needed to kill cancer cells through laser light radiated directly
into the cells. Further, the laser of preference is stated to be Nd:YAG in
the belief that it penetrates tissue deeper than other types of medical
lasers.
Temperature distribution through tissue varies, depending on the color of
the organ, the rate of blood flow through the organ, and the level of
energy applied. In the "LASERTHERMIA . . . " article cited above, a
thermogram comparison made in heat conductivity studies on spleen tissue
showed the tissue temperature ranged from 50.degree. C. at the heat source
to 43.degree. C. six millimeters away, with laser energy input of
approximately 5 watts.
Recognizing the importance of keeping the tissue temperature high enough to
destroy cancer cells, some prior medical researchers have implanted
thermocouples in the tissue to be treated. In applicant's copending
application Ser. No. 07/534,931, separate, parallel needles are glued
together, 3 mm. apart. One carries an optical fiber and the other carries
a temperature-sensing thermocouple. While this is useful as a research
tool, it would have serious disadvantages in the real world of practical
medical treatment.
In the example mentioned above where the implanted thermocouples were
stationary, they could be used only with stationary laser probes because
movement of the probes would make the temperature readings meaningless.
Even in the case of the double needle embodiment disclosed in applicant's
copending application, it would be very difficult to precisely control the
spacing between the thermocouple and the laser tip, especially with long
probes. Further, it would require multiple stab incisions or a relatively
large incision.
SUMMARY OF THE INVENTION
Accordingly, it is an object of the present invention to provide an
apparatus and method for treatment of tumor tissues located inside organs
within the body by laser-induced hyperthermia and coagulative necrosis,
with improved precision control of the tissue temperature.
Another object of this invention is to provide an apparatus and method for
accurately monitoring the temperature of the tumor tissue being treated by
securing a temperature sensing element directly to a laser energy
transmitting probe which is insertable directly in the tumor tissue.
Another object of this invention is to provide an apparatus and method for
simultaneously monitoring the temperature of tumor tissue within which a
laser energy transmitting probe is inserted while moving the probe
throughout the tissue at a speed which will heat successive regions of the
tissue uniformly to a predetermined therapeutic temperature range during
movement of the probe.
Another object of the invention is to provide an apparatus and method for
moving a laser energy transmitting probe through a tumor tissue while
monitoring the temperature of the tissue at the probe and regulating the
speed of movement of the probe to maintain the temperature at the probe
within a predetermined therapeutic temperature range.
Another object of the invention is to provide an apparatus and method for
moving a laser energy transmitting probe through a tumor tissue while
monitoring the temperature of the tissue at the probe and regulating the
energy input to the probe to maintain the temperature of the tissue at the
probe within a predetermined therapeutic temperature range.
Another object of the invention is to provide apparatus for interstitial
laser therapy comprising a thin cannula, an optical fiber extending
through a lumen in the cannula to conduct laser energy to a tissue mass in
which the distal end portion of the cannula is inserted, and a temperature
sensing element secured to the surface of the cannula at the distal end
portion and movable therewith.
Another object of the invention is to locate the temperature sensing
element rearwardly of the distal tip of the cannula a sufficient distance
to render the temperature sensing element sensitive primarily to the heat
of the tissue mass in which the distal end portion of the cannula is
inserted.
Another object is to provide, on the temperature sensing element and
adjacent portion of the cannula, a highly reflective coating having
reflectivity in the order of gold plating, enabling the temperature
sensing element to respond primarily to heat conducted from tissue in
which the distal end portion of the cannula is inserted, and not from heat
reflected directly or indirectly from the tip of the optical fiber.
Another object is to provide the temperature sensing element in the form of
a miniature thermocouple or thermistor at the forward end of a miniature
tube which is smoothly soldered or otherwise inconspicuously secured along
the outside of the cannula.
BRIEF DESCRIPTION OF THE DRAWINGS
Other objects and advantages will be apparent from the following drawings
in which:
FIG. 1 shows a schematic representation of a side view of the apparatus of
the present invention illustrating the cannula, the optical fiber, the
temperature sensing element secured to the outside of the cannula, a
commercially available Y-connector supporting the cannula, a longitudinal
positioning stop for the optical fiber, a tissue mass into which the
cannula is inserted, and components for operating in a manual mode or in
optional automatic modes;
FIG. 2 is a fragmentary enlarged view of FIG. 1;
FIG. 3 is a greatly enlarged cross sectional view of FIG. 1 taken along
line 3--3; and
FIG. 4 is a fragmentary enlarged view of the distal end portion of the
cannula with a pointed stylet inserted therein to facilitate insertion
into a tissue mass to be treated.
Like parts are designated by like reference characters throughout the
figures of the drawing.
DESCRIPTION OF THE PREFERRED EMBODIMENT
Referring now to the embodiment shown in the drawings, the apparatus is
generally designated 20. This comprises a thin needle cannula or probe 22,
an optical fiber 24, a laser 26, a pump 28, a source of physiologically
acceptable fluid 29, temperature sensing means 30, and a Y-connector 32.
The needle cannula 22 may be an extra thin 19-gauge stainless steel needle
(1.1 millimeter outside diameter, and less than 100 microns wall
thickness). Alternatively, it may be made of an anatomically acceptable
plastic or elastomeric material having suitable rigidity. The internal
diameter of the lumen 34 in the cannula is sufficiently large to allow for
easy location of the optical fiber 24 as well as to permit para-axial flow
of a cooling fluid such as normal saline from pump 28 and a syringe or
other source 29. The cannula may be any suitable length, e.g., 10-15 cm,
to reach tissue masses to be treated which are distant from the skin
surface.
The optical fiber for use with the cannula may be a 600 micron diameter
quartz optical fiber having a divergence angle of 8.degree. and it will be
stripped of its terminal plastic coating sufficiently to allow the
stripped portion to be inserted through the lumen 34. Smaller diameter
optical fibers can be employed for the purposes of the present invention,
allowing smaller cannulae to be used, thereby significantly diminishing
the adverse effects of insertion of the apparatus into deeply-lying tumors
in otherwise healthy tissue.
The laser 26 is preferably a Nd:YAG laser generating radiation coupled into
optical fiber 24 which passes through the Y-connector 32.
The fluid pump 28 may be a micro pump supplying, for example, normal saline
fluid through the annular space 36 (FIG. 3) between the cannula 22 and
optical fiber 24. As described in applicant's co-pending application Ser.
No. 07/534,931, this normal saline acts as a cooling fluid and also
provides a heat transfer and dispersing medium for the laser energy from
the optical fiber tip to the tissue mass being treated, thereby avoiding
direct heat concentration and possible charring of tissue at the distal
tip end of the optical fiber. Prior to insertion, the position of the
optical fiber in the cannula is adjusted so that the distal tip is
approximately flush with the tip of the cannula 22 before tightening the
proximal screw 38 of the Y connector 32. If the distal tip of the fiber is
located significantly inside of the cannula, excessive heating of the
cannula results, while if the tip is located significantly forwardly of
the cannula tip, the saline fluid is ineffective. In practice the fiber
tip may extend up to about a millimeter beyond the cannula tip. Fluid pump
28 is connected to arm 40 of Y-connector 32.
Laser 26 has a laser rod 42, a resonant mirror 44, and a shutter 46 between
them. The emission of a laser beam from the source 26 is controlled by the
shutter 46. Laser energy output in watts may be indicated by dial 47 on
the outer casing. The laser 26 directs laser energy into the optical fiber
24. A stop collar 48 is secured on the optical fiber to fix the horizontal
position of the distal tip approximately flush with the tip of the cannula
22. A second, straight arm 50 of Y-connector 32 guides the optical fiber
into the coupling 52 at the proximal end of the cannula.
The temperature sensing means 30 may for example be a 0.010 inch micro
thermocouple (Omega, Conn.). This is soldered smoothly to the outside of
the needle cannula with its tip located one millimeter proximal to the tip
of the cannula. Referring to FIG. 4, the dimension A is one millimeter. As
shown in the cross section of FIG. 3, a pair of conductors 54, 56 extend
rearwardly through insulation 58 within a mini tube or casing 60 connected
as by solder 62 along the outside of the cannula 22.
In using the apparatus to ablate a tumor, the size and dimensions of the
tumor will first be determined. Correct measurement of the tumor is
important in using the apparatus and method of this invention. The laser
energy and exposure time for a particular tumor will be determined from
data tables prepared in advance from prior hyperthermia tests with similar
apparatus on various size tumors in animal and human subjects. With
presently available medical imaging technology such as computerized
tomagraphy and ultrasound, it is possible to measure tumor volumes both
pre-, intra- and post-operatively. Information derived from this type of
investigation makes it possible to calculate the total amount of energy in
joules (watt-seconds) required for an average 2-3 centimeter diameter
tumor occurring in the breast and liver. Previous investigators have
reported the penetration of Neodymium:Yttrium-Aluminum-Garnet (Nd:YAG)
laser light and "cell kill" to range between 3-8 millimeters for both
contact and interstitial applications ("Nd:YAG Laser-Induced Hyperthermia
in a Mouse Tumor Model"-Lasers in Surgery and Medicine, 1988; 8:510-514).
Factors such as tumor type, pigmentation of the tissue mass, vascularity,
and type of laser energy will influence the ablative outcome.
In operation, a stylet 64 will be assembled in the cannula with the point
66 extending from the distal end as shown in FIG. 4. The length of the
cannula and stylet will be determined by the depth of the tumor within the
body. Under general anesthesia, the cannula and stylet will be inserted
through a small stab incision in the skin and guided precisely through
normal tissue 69 into the tumor mass 68 using known medical imaging
technology. The cannula needle with the stylet 64 is inserted along the
longitudinal axis of the tumor mass 68 to the far end as shown in FIG. 1.
The stylet will then be withdrawn and replaced by the optical fiber 24
with the tip flush with the distal end of the cannula as determined by the
stop collar 48. This is shown in FIGS. 1 and 2. At this time, the
mini-pump 28 is started and draws normal saline from source 29 and flows
it into the annular space 36 between the optical fiber 24 and cannula 22.
This causes a continuous flow of saline, for example in the order of one
cubic centimeter per minute. The fluid exiting the distal end of the
cannula produces a bolus 80 of liquid which prevents overheating damage to
the fiber tip, and acts as a lens transmitting and dispersing laser light
energy transversely of the optical fiber tip. As reported in the article
entitled "LASERTHERMIA . . . " cited above, where the temperature in the
immediate vicinity of an interstitial probe was held at 50.degree. C., the
temperature 6 to 7 millimeters away (at the radius R, FIG. 1) was
maintained at 42.degree.-43.degree. C. which resulted in tumor necrosis of
70%-80% within 7 days.
Applying the above heat distribution findings in the practice of this
invention to FIG. 1, laser 26 is fired until the temperature sensed by the
thermocouple 30 is 50.degree.-51.degree. C. This means that the
temperature at the radius R is 42.degree.-45.degree. C. Then, by
withdrawing the cannula, in the direction of the arrow X, at a speed
sufficient to keep the temperature at the thermocouple between
50.degree.-51.degree. C., the tumor mass 68 will be effectively locally
destroyed at least out to the radius R with minimal loss of normal tissue.
For larger tumors, multiple passes may be made with the cannula, or in
some cases the laser energy level may be increased. However, excessively
high levels of energy should be avoided to avoid liquifaction. The
thermocouple 30 and mini-tube 60 will preferably be gold plated to prevent
transmission of heat from the bolus 80 by direct or indirect reflection;
thereby rendering the thermocouple 30 primarily responsive to heat
received from the tumor mass by conduction. This greatly improves the
accuracy of temperature measurement at the thermocouple tip 30.
In practicing the invention, the following three modes of operation are
available to maintain a predetermined therapeutic temperature in the tumor
tissue mass while withdrawing the cannula: (1) a manual mode; (2) a first
automatic mode in which speed of movement of the cannula varies
automatically in response to tissue temperature; and (3) a second
automatic mode in which laser input energy varies automatically in
response to tissue temperature.
Referring first to the manual mode, the cannula 22 is fitted with a pointed
stylus 64 as shown in FIG. 4 and introduced through a small stab incision
and guided by conventional medical imaging technology and is inserted
preferably along the longitudinal axis to the far end of the mass. The
stylet will be removed and replaced by the optical fiber as shown in FIGS.
1 and 2. The size of the tumor will already have been determined by
previous medical imaging and the laser energy and exposure time for the
particular tumor will have been determined from data tables prepared in
advance as stated above.
For example, if the tumor has a 6 mm radius and the data tables show that a
5-watt energy input by the laser 26 will produce a temperature of
50.degree.-51.degree. C. on the outer surface of the distal end of the
cannula sensed by the thermocouple 30, and this in turn will produce a
temperature of 42.degree.-45.degree. C. at the radius R=6 mm, this is
sufficient to destroy a circular area of similar tumor tissue having the
same 6 mm radius. At the outset, the surgeon or technician allows a few
drops of saline to flow through the annular space 36 to displace any air,
tissue debris or blood clots entrained therein. The saline pump 28 will be
adjusted at a desired rate, typically, one cubic centimeter per minute,
enough to establish a fluid pool or bolus 80 in front of the distal tip of
optical fiber 24 as described in applicant's copending application Ser.
No. 07/534,931 to which reference may be made for details. Next, the laser
is activated and set for an output of 5 watts. When the temperature gauge
33 indicates that the temperature at thermocouple 30 is in the
predetermined range of 50.degree.-51.degree. C., the motor 84 is activated
in a rearward direction. Speed is regulated by the manual motor control 86
to keep the tissue temperature at the thermocouple in that predetermined
range so the temperature at the radius R (FIG. 1) reaches
42.degree.-45.degree. C. progressively along the axis of the cannula to
thereby coagulate a cylindrical volume 82 of tissue as the cannula is
withdrawn. This movement is observed by medical imaging and terminated
when the tip of the cannula reaches the proximal end of the tissue mass.
In practicing the invention by the first mentioned automatic mode, after
the cannula is inserted in the tumor mass 68, and the bolus 80 is
established by saline pump 28, the output energy of laser 26 may be set at
5 watts, for example. An automatic motor control unit 100 is schematically
shown connected between the temperature gauge 33 and motor 84. Control
unit 100 will be set to activate motor 84 in a direction to reverse-rotate
screw 90 and thereby withdraw the cannula 22 when the temperature sensed
by gauge 33 reaches 51.degree. C. or more, and to stop when the
temperature is at 50.degree. C. or less. Thus control 100 and motor 84
automatically regulate the withdrawal rate to maintain the tissue
temperature within the predetermined therapeutic range which in this
example is assumed to be 50.degree.-51.degree. C. at the surface of the
cannula and corresponds to 42.degree.-45.degree. C. at radius R.
In practicing the invention by the second mentioned automatic mode, after
the cannula is inserted in the tumor mass 68, and the bolus 80 is
established by saline pump 28, the motor 84 will be turned on and set at a
desired reverse speed by control 86. Automatic laser control 110 is
connected between temperature gauge 33 and energy output control shutter
46 of laser 26. Control 110 will be set to turn the laser on when the
temperature sensed by thermocouple 30 is 50.degree. C. or less and to turn
the laser off when the temperature sensed by the thermocouple is
51.degree. C. or above. Thus, control 100 and laser 26 automatically
regulate the energy input through the optical fiber to maintain the tissue
temperature within the predetermined therapeutic temperature range.
In order that those skilled in this art may better understand the
invention, the following detailed description taken from clinical tests is
presented in detail.
EXAMPLE
Laser Probe
A prototype probe as shown in FIG. 1 was employed in this investigation. It
consisted of a 10 cm long 19-gauge needle cannula 22 containing a stylet
64 which facilitated the initial insertion and was subsequently replaced
by the laser optical fiber 24. A 0.010 inch micro thermocouple 30 (Omega,
Conn.) was soldered employing pure tin to the outside of the needle
cannula with its tip located exactly one millimeter proximal to the tip of
the cannula. This complex was gold plated to reflect direct laser light.
The plug 35 on the proximal end of thermocouple conductors 54, 56 was
connected to the temperature gauge 33 for continuous temperature display.
This plug was secured to the hub of the needle cannula by epoxy. A 600
micron bare tip quartz fiber was stripped of its terminal 10.5 cm cladding
and passed through the straight arm 50 of the Y-connector 32 (Advanced
Cardiovascular System, Calif.) Its position was fixed by tightening the
screw 38 around the laser fiber cladding, so that the bare tip on the
distal end would protrude less than one millimeter from the end of the
cannula. In other words, the tip of the optical fiber was very slightly
outwardly located from a flush position with respect to the distal end of
the cannula.
Tumor Model
Virgin, female Sprague-Dawley rats at 50 days of age and approximately 200
grams were injected with N-methyl-N-nitrosourea at a dose of 40 milligrams
per kilogram body weight to induce mammary carcinomas. After an interval
of approximately 2 months, each animal was palpated once a week to assess
tumor growth. Tumors measuring 2 centimeters in diameter or larger were
selected for this experiment.
Methods
The animals were anesthetized with an intramuscular injection of ketamine
at a dose of 44 milligrams per kilogram body weight. The hair around each
tumor and surrounding area was shaved and the tumor dimensions were
measured with a caliper. The tumor was immobilized without occluding its
blood supply with a non-crushing clamp. The cannula 22 with a stylet 64 in
the cannula was inserted along the longitudinal axis of the tumor 68 and
was advanced until its tip could be palpated subcutaneously on the
opposite pole of the tumor. The stylet 66 was removed and the laser fiber
24, already fixed inside the "Y" shaped connector 32 to a predetermined
length, was inserted in the needle cannula 22, and the tightening screw 38
was tightened on the cannula. Arm 40 of the Y-connector 32 was attached to
a syringe 39 filled with normal saline and placed in a Harvard pump 28
(Harvard Biosciences, Me.) This allowed a continuous flow of saline (1
cc/min) to prevent damage to the fiber tip during irradiation. This is
described in "Lasers in Surgery and Medicine", 10:322-327 (1990), in an
article by Kambiz Dowlatshahi, Julie D. Bangert, Michael F. Haklin,
Charles K. Rhodes, Ronald S. Weinstein, and Steven G. Economou, entitled
"PROTECTION OF FIBER FUNCTION BY PARA-AXIAL FLUID FLOW IN INTERSTITIAL
LASER THERAPY OF MALIGNANT TUMOR". The "thermo-laser probe" was attached
to a Sears Lathe and set to move out of the tumor.
Five animals, with one tumor each, were allocated to each of five levels of
laser irradiation: 500, 750, 1000, 1500 and 2000 joules (J), respectively.
Tumors measuring 2 cm in diameter were chosen for up to 1000 J irradiation
and 3 cm tumors for the 1000-2000 J experiments. There were two control
groups with 5 tumors in each. In the first control group, the laser probe
was inserted and saline administered (1 cc/min) as the probe was withdrawn
but no laser energy was given. In the second control group, the tumors
were excised and sectioned without probe insertion to assess the degree of
spontaneous necrosis. At the outset, approximately 0.5 cc of saline was
allowed to flow before activating the laser at a power setting of 5 watts.
Once the temperature reached 42.degree. C., the laser probe was slowly
withdrawn at a speed to ensure that the temperature of the tumor remained
between 42.degree.-45.degree. C. The fiber transmission was tested at the
beginning and at the end of each experiment using a power meter
(Trimedyne, Calif.).
48 hours later, again under general anesthesia, the laser treated tumors
and tumors from the first control group were excised and fixed in 10%
buffered formalin. The tumors which were liquified or partially ulcerated
(total of 17), hence non-evaluable with respect to volume determination,
were excluded and replaced. Intact tumors were serially sectioned in 3 mm
slices, and representative sections were taken from each block and stained
with hematoxylin and eosin. Each section was individually examined under
microscope employing a Nikkon Labophot with a 1X objective (Fryer, Ill.).
A JVC video camera in conjunction with a Macintosh II Image Studio program
was employed to measure the surface area of the necrotic tissue. The
coagulated volume of each block was determined by multiplying the mean
surface area of necrosis by the thickness of the block. The sum of the
individual necrotic volumes of all blocks was the total volume of
coagulated tissue caused by interstitial laserthermia in that tumor.
Results
The rat mammary tumors (adenocarcinomas) treated with Nd:YAG laser
hyperthermia in this study uniformly exhibited coagulation necrosis at 48
hours. Centrally, the cytoplasmic membrane of the cells was disrupted and
nuclear pyknosis was marked. Peripherally, although cell kill was still
evident, the overall outline of the lobule was preserved.
The volume of necrosis incrementally increased in tumors receiving greater
quantities of laser energy as shown in Table 1.
TABLE 1
______________________________________
VOLUME OF NECROSIS (cc)
TOTAL ENERGY (joules)
MEAN (RANGE)
______________________________________
0 0.2 (0.1-0.3)
500 0.8 (0.5-1.1)
750 1.2 (0.6-1.9)
1000 1.4 (1.3-1-6)
1500 2.4 (1.6-3.6)
2000 4.0 (2.1-5.2)
______________________________________
Isolated islands of necrosis, "skip lesions", were noted outside the main
ablated area, in tumors irradiated with 500-750 joules, but were not
included in the histologic measurement of their necrotic volumes. A linear
relationship was observed between laser energy and the volume of necrosis.
Since the necrotic volumes could not be adequately ascertained in the
liquified tumors, these were replaced. The following Table 2 illustrates
that 19 of the 44 tumors used in this study liquified and that the
incidence of liquefaction increased with greater levels of irradiation.
TABLE 2
______________________________________
LIQUIFIED TUMORS
JOULES NUMBER OF TUMORS (% OF TOTAL*)
______________________________________
500 1 (16%)
750 3 (36%)
1000 4 (44%)
1500 5 (50%)
2000 6 (56%)
______________________________________
*PERCENTAGE OF THE TOTAL NUMBER OF TUMORS TREATED IN THAT ENERGY CATEGORY
The results from these experiments indicate that continuous wave Nd:YAG
laser at 5 watts delivered interstitially through a mobile probe can
ablate 1 cc of rat mammary tumor in 2 minutes. If the tumor temperature is
maintained within 42.degree.-45.degree. C., the rate of fiber transmission
loss is less than 1% after 1000 J of irradiation.
Discussion
The tumor model chosen for this study was very cellular and moderately
vascular. The superficial location of the tumors along the mammary ridge
enabled the insertion of the laser probe into the central axis of the
tumor with relative ease and without the need for sonographic guidance.
Forty three percent of the treated tumors liquified of which 79% received
greater than 1000 J of energy. Even though tumors of larger size were
utilized for the higher energy levels, the incidence of liquefication
still increased. This may be a reflection of the limitation of this tumor
model to absorb high energy or simply the tumor outgrowing its blood
supply and to be susceptible to excessive necrosis.
The para-axial fluid flow allowed the coagulation of a 2 cm tumor within 10
min using continuous wave Nd:YAG laser set at 5 watts with minimal damage
to the fiber tip. Initially a power setting of 10 watts was employed to
accelerate the process and shorten the operation time but this higher
power setting resulted in more damage to the laser fiber tip,
necessitating replacement.
SUMMARY OF THE EXPERIMENTAL TESTS
The extent of coagulative necrosis caused by interstitial laser
hyperthermia was measured for different quantities of laser energy in a
rat mammary tumor model. Continuous wave Nd:YAG laser at a power level of
5 watts was focused onto a 600 micron diameter bare tip quartz fiber and
placed inside a 19-gauge needle which allowed the para-axial flow of
normal saline at 1 cc/min. A microthermocouple soldered to the outside of
the probe continuously provided the interstitial temperature. After the
probe was inserted into the tumor, it was withdrawn as laser energy was
administered at a rate sufficient to maintain the temperature within
42.degree.-45.degree. C. Tumors were excised after 48 hours, fixed in
formalin, cut in 3 mm slices and the coagulated surfaces measured
microscopically. Laser fiber transmission loss was 1% per 1000 joules of
laser energy and the average time required to coagulate 1 cc of tumor was
2 minutes. The mean volume of tumor necrosis of five experiments at each
level of laser irradiation was:
______________________________________
Laser energy (joules)
500 750 1000 1500 2000
Tumor necrosis (cc)
0.8 1.2 1.4 2.4 4.0
______________________________________
It is concluded that the described technique is an efficient method of
tumor coagulation by interstitial laser hyperthermia and proportionally
larger volumes of necrosis are created with greater amounts of laser
energy.
While the above description illustrates specific apparatus and methods for
practicing this invention, the invention is not limited thereto and
includes all embodiments which would be apparent to those skilled in the
art.
* * * * *
|
|
|
|
|
Description  |
|